Phase 4 N=28 Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin
Healthy
Primary: NK-104 AUC — 208.92 ng * h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Phase 1 N=30 Transporter Cocktail Mutual Interaction
Healthy
Primary: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) — 11.549; 11.981 nanomole hour per liter (nmol·h/L)
Phase 1 N=24 Drug-Food Interaction Study of Seville Orange Juice and Colchicine
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Colchicine — 2,328.44; 1,668.33 pg/mL
Phase 1 N=29 Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
Phase 1 N=22 A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,172.96; 1,971.10 pg/mL
Phase 1 N=64 Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 94.37; 43.84; 106.35; 51.65 ng/mL
Phase 1 N=18 A Food-Drug Interaction Study of Serum Urate After Oral Inosine
Healthy
Primary: Cmax: Maximum Observed Serum Urate Concentration — 6.6; 6.4 mg/dL
Phase 1 N=16 DDI Between BI Empagliflozin (10773) and Verapamil
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5190; 5340 nmol*h/L
Phase 1 N=13 Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics
Healthy Volunteers
Primary: Maximum Drug Concentration of Metformin in Plasma After Single Dose Administration (Cmax) — 1550; 1460 microgram per liter (mcg/L)
Phase 1 N=30 Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
Healthy
Primary: Area Under the Plasma Concentration Curve (AUC) at Steady State for Metronidazole — 217686; 215809 ng*h/ml
N/A N=19 Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
HIV
Primary: AUC — 94.17; 34.67; 100.44; 32.58 h*microgram/mL
Phase 1 N=24 Drug-Drug Interaction Between Colchicine and Ritonavir
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 1,869.50; 4,993.06 pg/mL
Phase 3 N=12 Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects
Clinical Pharmacology
Primary: AUC (0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Postdose for Unchanged SYR-322 (SYR-322Z) — 1494.9; 1472.8 nanogram*milliliter per…
Phase 1 N=20 Interaction of BI 691751 With Itraconazole
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 up to the Last Quantifiable Concentration) — 2830…
Phase 1 N=42 SSP-002358 Drug Interaction Study With Omeprazole
Healthy
Primary: Maximum Plasma Concentration (Cmax) for SSP-002358 — 3.89; 4.12 ng/ml
Phase 1 N=16 Drug-drug Interaction of BI 201335 and Microgynon
Hepatitis C, Chronic
Primary: AUCt,ss of Ethinylestradiol — 1010; 1450 pg*h/mL
Phase 4 N=10 Drug-Drug Interaction Between Rifampin and Fluvastatin
Drug-drug Interaction
Primary: AUC — 242; 642; 124; 371 ng/mL·h
Phase 1 N=51 Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
COVID-19
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity [Extrapolated] (AUC0-inf): ALG-097558 in Part A and Part C, Dabigatran (Total) in Plasma in Part B…
Phase 1 N=54 Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
Type2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 124.6; 135.5; 158.6; 143.7 ng/mL
Phase 1 N=24 Drug-Drug Interaction Between Colchicine and Verapamil ER
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,968.42; 3,850.63 pg/mL
Phase 4 N=28 Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin
Healthy
Primary: NK-104 AUC — 192.00 ng * h/mL
N/A N=348 Emergency Department (ED) Drug Interaction in Emergency Department Patients
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
Phase 1 N=30 Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Efavirenz — 2,461.58; 2,384.79 ng/mL
N/A N=18 Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?
Food-drug Interaction
Primary: Primary Pharmacokinetic Measure: Area Under the Curve (AUC) — 4.2; 4.2; 4.2; 3.2 micromolar*hr — p=0.78
Phase 1 N=11 Doravirine, Rifapentine and Isoniazid Interaction
Latent Tuberculosis · Human Immunodeficiency Virus · Rifamycins Causing Adverse Effects in Therapeutic Use
Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL
Phase 1 N=32 Food and Insulin Effect on QT/QTC Interval of ECG
Effects of Different Meals on the QT/QTc Interval · Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use · C-Peptide Effects on the QT/QTc Interval
Primary: The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin — 14.4; 11.6 ms — p=0.05
Early Phase 1 N=22 Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Interaction, Adverse Herb-Drug · Diabetes Mellitus, Type 2
Primary: Metformin AUC — 59.6; 54.5; 57.3 mcg*hr/mL
Phase 1 N=24 Drug-Drug Interaction Study Between Colchicine and Diltiazem ER
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Primary: Maximum Plasma Concentration (Cmax) — 2,172.32; 2,802.90 pg/mL
Phase 1 N=12 Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.
Erectile Dysfunction
Primary: Maximum Observed Plasma Concentration (Cmax) — 292.60; 121.00 ng/mL